Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

5.22
+0.11002.15%
Volume:312.28K
Turnover:1.60M
Market Cap:163.33M
PE:-1.26
High:5.24
Open:5.06
Low:5.01
Close:5.11
52wk High:50.40
52wk Low:4.54
Shares:31.29M
Float Shares:18.39M
Volume Ratio:1.43
T/O Rate:1.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.74
PE(LYR):-1.83

Loading ...

Tenax Therapeutics announces results from Phase 3 LEVEL trial of TNX-103

TIPRANKS
·
Yesterday

Ocumension Therapeutics (SEHK:1477) Stock Growth Story Runs Into Funding Risk

Simply Wall St.
·
Aug 30

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

GlobeNewswire
·
Aug 29

Biotech Firm Electra Therapeutics Files for Nasdaq Debut Amid Sector IPO Surge

Stock News
·
Aug 29

Sharp Therapeutics trims H1 R&D spend, raises C$1.4 million to fund genetic disease pipeline

TIPRANKS
·
Aug 29

Spero Therapeutics Launches New Jefferies ATM Equity Program

TIPRANKS
·
Aug 29

Obsidian Therapeutics files to sell 29.16M shares of common stock for holders

TIPRANKS
·
Aug 29

Spero Therapeutics files $300M mixed securities shelf

TIPRANKS
·
Aug 29

Sangamo Therapeutics Signs Asset Sale Deal Amid Bankruptcy

TIPRANKS
·
Aug 29

Electra Therapeutics Files for IPO

Dow Jones
·
Aug 29

Alterity Therapeutics Reaffirmed at Buy as Pivotal Phase 3 Nears; $16 Price Target Maintained

TIPRANKS
·
Aug 29

Aprea Therapeutics Expands Global IP for Precision Oncology

TIPRANKS
·
Aug 28

Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs

GlobeNewswire
·
Aug 28

Kazia Therapeutics 2.58M share Spot Secondary priced at $15.50

TIPRANKS
·
Aug 28

BioXcel Therapeutics Initiates Chapter 11 and Sale Process

TIPRANKS
·
Aug 28

Kazia Therapeutics Cuts ATM Offering Capacity to $80 Million

TIPRANKS
·
Aug 28

BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals

GlobeNewswire
·
Aug 28

PYC Therapeutics Files 2026 Corporate Governance Statement with ASX

TIPRANKS
·
Aug 28

PYC Therapeutics Details Governance and Operations in 2026 Annual Report

TIPRANKS
·
Aug 28

PYC Therapeutics Narrows Loss and Strengthens Balance Sheet in FY2026

TIPRANKS
·
Aug 28